Membranous nephropathy
(
00:00
/30:04)
Outline
1, MEMBRANOUS NEPHROPATHY
2. Objectives
3. Trends in the progressive
4, What the Patient wants to
5. Predicting Factors
6. Phospholipase A2 Receptor
7, Relevance of MGN Ab to ma
8. Outcome by Age is not rel
9. Effect of Sex on Outcome
10, Age and sex of the patie
11, Graphic illustration of
12, Advantages
13.
14, And no relationship of t
15, Compared to no relations
16. Risk of Progression Cate
17. To sum up prognostic ind
18, Proteinuric CKD patients
19. No remission vs Partial
20. Also rate of progression
21. Risk of Progression Cate
22. Specific Treatment
23.
24.
25.
26. Effects of second course
27. Risk of malignancy relat
28. Cyclophosphamide and inf
29.
30.
31. Contrasting results MMF
32. Risk of cancer in MGN vs
33.
34.
35.
36. CNI'S
37. Other Rx Protocols
38. ACTH response(one year o
39.
40. Proteinuria response Sin
41. Prolonged remission with
42. MGN
43. Major Points
44. MGN TREATMENT ALGORITHM
Thumbnails
1, MEMBRANOUS NEPHROPATHY
2. Objectives
3. Trends in the progressive
4, What the Patient wants to
5. Predicting Factors
6. Phospholipase A2 Receptor
7, Relevance of MGN Ab to ma
8. Outcome by Age is not rel
9. Effect of Sex on Outcome
10, Age and sex of the patie
11, Graphic illustration of
12, Advantages
13.
14, And no relationship of t
15, Compared to no relations
16. Risk of Progression Cate
17. To sum up prognostic ind
18, Proteinuric CKD patients
19. No remission vs Partial
20. Also rate of progression
21. Risk of Progression Cate
22. Specific Treatment
23.
24.
25.
26. Effects of second course
27. Risk of malignancy relat
28. Cyclophosphamide and inf
29.
30.
31. Contrasting results MMF
32. Risk of cancer in MGN vs
33.
34.
35.
36. CNI'S
37. Other Rx Protocols
38. ACTH response(one year o
39.
40. Proteinuria response Sin
41. Prolonged remission with
42. MGN
43. Major Points
44. MGN TREATMENT ALGORITHM
Notes
MAU: Summary
Time: 01 min 17 sec
Search
Search in
Slide text
Slide notes
Slide titles
References
Slide
01
/44
00:00
/ 30:04
